Greenbrier Tip-Off Mountain Division set for Friday and Sunday at The GreenbrierUS agencies should use advanced technology to identify mysterious drones, Schumer saysBLACKSBURG, Va. — Pop Watson threw for 254 yards and a touchdown and rushed for a score to lead Virginia Tech to a 37-17 victory over rival Virginia on Saturday. Bhayshul Tuten added 124 yards rushing and two scores for the Hokies (6-6, 4-4 Atlantic Coast Conference), who snapped a three-game losing streak. The Hokies also became bowl eligible for the second straight year with the victory. Virginia (5-7, 3-5) lost to Virginia Tech for the fourth straight time and for the 22nd time in the past 24 meetings. With Virginia Tech’s top two quarterbacks, Kyron Drones and Collin Schlee, injured, Watson made his first career start and led the Hokies on four first-half scoring drives. The Hokies jumped out to a 10-0 lead, getting a 6-yard touchdown run from Tuten and a field goal from John Love on their first two possessions. They then scored 10 points in the final two minutes of the first half, getting a 66-yard scoring strike from Watson to Jaylin Lane and then closing the half with another field goal from Love to take a 20-3 lead. In the second half, Watson scored on a 5-yard run on the Hokies’ opening possession. The redshirt freshman finished with 48 yards rushing and accounted for 302 yards of the Hokies’ 456 yards of offense. Tony Muskett, making his first start of the season, led Virginia, throwing for 178 yards and rushing for 62 yards and two touchdowns. Virginia Tech's William "Pop" Watson III (18) hands off to Bhayshul Tuten (33) during the first half of an NCAA college football game against Virginia, Saturday, Nov. 30, 2024, in Blacksburg, Va. Credit: AP/Robert Simmons TAKEAWAYS Virginia: The Cavaliers improved by two wins from last year’s record under third-year coach Tony Elliott, but closed the season by losing six of their final seven games, and they still haven’t found an answer against the rival Hokies. Seventeen of their 22 losses to Virginia Tech during this recent streak have been by double figures. Virginia Tech: The Hokies have been one of the nation’s bigger disappointments this season, but behind Watson, they again managed to secure bowl eligibility with a win over Virginia. Virginia Tech has entered its rivalry game needing a win to become bowl eligible seven times in the past 12 seasons - and won all seven games. UP NEXT Virginia Tech's Jaylin Lane runs after catching a long ball for a touchdown against Virginia during the first half of an NCAA college football game Saturday, Nov. 30, 2024, in Blacksburg, Va. Credit: AP/Robert Simmons Virginia: The Cavaliers’ season is over. Virginia Tech: The Hokies are awaiting their bowl opponent.
Objects thrown as Man City and Feyenoord fans clash during Champions League tie
Published 6:39 pm Saturday, November 30, 2024 By Data Skrive The injury report for the Cleveland Cavaliers (17-3) ahead of their game against the Boston Celtics (16-3) currently includes three players. The Celtics have four injured players listed on the report. The matchup is slated for 6:00 PM ET on Sunday, December 1. Watch the NBA, other live sports and more on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Use our link to sign up for a free trial. The Cavaliers are coming off of a 117-101 loss to the Hawks in their last game on Friday. In the Cavaliers’ loss, Darius Garland led the way with a team-high 29 points (adding three rebounds and five assists). In their most recent outing on Friday, the Celtics claimed a 138-129 victory over the Bulls. Jayson Tatum scored 35 points in the Celtics’ victory, leading the team. Name Position Status Injury PPG RPG APG Max Strus SF Out Ankle Emoni Bates SF Out Knee Dean Wade PF Out Ankle 5.5 4.2 1.5 Sign up for NBA League Pass to get live and on-demand access to NBA games. Name Position Status Injury PPG RPG APG Jrue Holiday PG Questionable Groin 12.1 4.3 3.9 Kristaps Porzingis PF Questionable Knee 18.5 7.0 1.5 Al Horford C Questionable Toe 9.5 5.1 2.4 Derrick White SG Questionable Foot 18.3 4.7 4.4 Get tickets for any NBA game this season at StubHub. Catch NBA action all season long on Fubo. Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER .Published 4:38 pm Thursday, November 21, 2024 By Rocky Hulne From left, Savile Lord, Nick Novotny, Theresa Myers, Jason Sehon, Bonnie Reitz and Gretchen Boldt all celebrated the 30th annual fund raising kick-off for the downtown flowers. On display is a photograph taken by Tim Reitz during an Austin Art Works Festival. Rocky Hulne/sports@austindailyherald.com The downtown project already has Austin in the festive spirit for the holidays. Rocky Hulne/sports@austindailyherald.com It has now been three decades since the Flower Basket Program has made downtown Austin a beautiful place to visit in the summer, and it doesn’t look to be stopping anytime soon. Organizers of the program gathered downtown to celebrate the tradition and to kickoff its annual fundraiser. The program receives its funding from three sources — the City of Austin, donations from Hormel and donations from local people and businesses. Last year, there were over 110 local donors. The goal for this year is to raise $15,000. “ We want to say thank you to anyone who’s donated and If anybody’s looking for a Christmas present, you can donate flowers in someone’s honor,” organizer Bonnie Rietz said. Savile Lord of the SPAM Museum said that the Flower Project is always noticed by out of town visitors. Besides the summer flowers, the project also brightens downtown Austin with winter decorations and fall potted flowers as well. “As we bring in hundreds of thousands of visitors to Austin to celebrate the SPAM Museum and the SPAM brand, I cannot tell you the number of people who comment on how beautiful our downtown looks,” Lord said. “It makes it so warm, it makes it so inviting and it’s such a pleasure to look at every day.” Nick Novotny of IMPACT Austin said the project has helped keep the theme of Austin being a welcoming community. “We’re looking to make Austin a more welcoming place and having a really vibrant place with flowers in the summer, along with fall and winter displays make it very welcoming,” he said. You can donate to the flowers by writing a check to the city of Austin and sending it to city hall at 500 4th Ave NE. Be sure to write “flowers 2025” in the memo line. Donations via credit card may also be made over the phone by calling city hall at 437-9940.
Keene State men post 75-71 hoops win over Williamstown
Intech Investment Management LLC purchased a new stake in shares of Cross Country Healthcare, Inc. ( NASDAQ:CCRN – Free Report ) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 57,144 shares of the business services provider’s stock, valued at approximately $768,000. A number of other hedge funds also recently modified their holdings of CCRN. Pacer Advisors Inc. increased its holdings in Cross Country Healthcare by 3.8% in the second quarter. Pacer Advisors Inc. now owns 4,550,848 shares of the business services provider’s stock valued at $62,984,000 after purchasing an additional 165,032 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Cross Country Healthcare by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,360,016 shares of the business services provider’s stock valued at $32,662,000 after buying an additional 24,363 shares during the last quarter. Royce & Associates LP increased its stake in shares of Cross Country Healthcare by 51.4% in the third quarter. Royce & Associates LP now owns 1,132,566 shares of the business services provider’s stock valued at $15,222,000 after buying an additional 384,374 shares during the period. American Century Companies Inc. raised its position in shares of Cross Country Healthcare by 15.9% during the second quarter. American Century Companies Inc. now owns 772,834 shares of the business services provider’s stock worth $10,696,000 after acquiring an additional 106,226 shares during the last quarter. Finally, Dana Investment Advisors Inc. lifted its stake in shares of Cross Country Healthcare by 34.7% in the second quarter. Dana Investment Advisors Inc. now owns 404,370 shares of the business services provider’s stock worth $5,596,000 after acquiring an additional 104,136 shares during the period. Institutional investors and hedge funds own 96.03% of the company’s stock. Cross Country Healthcare Stock Down 0.4 % Shares of CCRN stock opened at $10.76 on Friday. The firm has a 50 day moving average of $11.79 and a 200-day moving average of $13.69. The company has a market cap of $354.19 million, a price-to-earnings ratio of -215.20, a price-to-earnings-growth ratio of 2.06 and a beta of 0.65. Cross Country Healthcare, Inc. has a 52 week low of $9.58 and a 52 week high of $23.64. Analysts Set New Price Targets Read Our Latest Analysis on CCRN Cross Country Healthcare Profile ( Free Report ) Cross Country Healthcare, Inc provides talent management and other consultative services for healthcare clients in the United States. The company’s Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel and local nurse and, allied professionals; temporary placement of healthcare leaders within nursing, allied, physician, and human resources; vendor neutral and managed services programs; education healthcare services; in-home care services; and outsourcing services. Featured Stories Want to see what other hedge funds are holding CCRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cross Country Healthcare, Inc. ( NASDAQ:CCRN – Free Report ). Receive News & Ratings for Cross Country Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cross Country Healthcare and related companies with MarketBeat.com's FREE daily email newsletter .NEWCASTLE, England (AP) — Newcastle’s winning run in the English Premier League came to an abrupt end when goals from Thomas Souček and Aaron Wan-Bissaka gave West Ham a surprise 2-0 win at St. James’ Park on Monday. The Hammers rose into 14th place and the pressure on coach Julen Lopetegui was eased.
Arsenal 5-1 Sporting (Nov 26, 2024) Game Analysis - ESPNLAS VEGAS — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. "As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It's an honor for General Motors and Cadillac to join the world's premier racing series, and we're committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM's engineering expertise and technology leadership at an entirely new level." The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti's IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports' NASCAR team and Wayne Taylor Racing's sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. "We're excited to partner with General Motors in bringing a dynamic presence to Formula 1," Towriss said. "Together, we're assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world." Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. "The Cadillac F1 Team is made up of a strong group of people that have worked tirelessly to build an American works team," Michael Andretti posted on social media. "I'm very proud of the hard work they have put in and congratulate all involved on this momentous next step. I will be cheering for you!" The approval has been in works for weeks but was held until after last weekend's Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night's race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti's dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years, and F1 initially denied the application despite approval from F1 sanctioning body FIA. The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they've already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti's application was the only one of seven applicants to meet all required criteria to expand F1's current grid. "General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners," Ben Sulayem said Monday. "I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application." Despite the FIA's acceptance of Andretti and General Motors from the start, F1 wasn't interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. "Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024," F1 said in a statement. "Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process." Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. "With Formula 1's continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport," Maffei said. "We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1."Managing forests with smart technologiesVice President Sara Duterte said she does not expect "fair treatment" from the government after appearing at House panel inquiry on the budget use of the OVP and Department of Education. "I do not expect fairness from this government. Really. Truly. That is the reason I am pussyfooting with ano, court cases," Duterte told reporters during an interview. "We do not expect fairness. Imagine mo. Saan ka makahanap.. na-admit na yung tao sa hospital bigla na lang papasok, discharged na siya in less than an hour. Saan ang hustisya diyan? Saan ang hustisya dito?" she added. She was referring to the order issued on the detention of lawyer Zuleika Lopez, chief-of-staff of Vice President Sara Duterte as she was cited in contempt. The Vice President also raised the alleged inaction of the government when she disclosed receiving threats. "Nag complain ako noon, if you can remember in the media and they dismissed it. Everything is well documented, with documents and videos," she said. "And then nagsabi ang NSC, na national security concern ang threat sa President. Pero, apparently, they really do not consider the threat to the Vice President as anything of a concern. So, what kind of country is this? Hindi ba ka-parte ng gobyerno ang vice president? Hindi ba ako binoto ng mga tao Hindi ba ako Vice President ng buong Pilipinas, ng lahat ng mga Pilipino?" she added. It can be recalled that Duterte made the kill remark early Saturday morning during a media conference at the House of Representatives where Lopez was detained. Answer cases in proper forum Duterte said she will "gladly answer" the questions that would be raised by the National Bureau of Investigation, but they should be able to answer her queries too. "Mag-uusap na lang kami doon pag nandyan na ang subpoena," she said. When asked whether Duterte has plans to file a case before the Supreme Court regarding the detention order issued by the House of Representatives, she replied "Parang... We don't trust any one anymore in this country." "We don't expect justice anymore in this country. It is clear political harassment. It is clear political persecution," she added. — BAP, GMA Integrated News
New state-of-the-art facility is among the first of its kind at a U.S. medical school Ribbon Cutting Photo L to R: Mount Sinai CEO Brendan G. Carr, Amabel James and Hamilton Evans "Tony" James, and Eric J. Nestler at a recent ribbon-cutting for the Hamilton and Amabel James Center for Artificial Intelligence and Human Health of the Icahn School of Medicine at Mount Sinai. The state-of-the-art research center solidifies Mount Sinai Health System's leadership in delivering patient care through groundbreaking innovation and technology. As one example, Mount Sinai was among the first academic medical centers in the United States to build and operate a supercomputer, named "Minerva," which went into service in 2013. The interdisciplinary center will combine artificial intelligence with data science and genomics in a location at the center of the campus of The Mount Sinai Hospital in Manhattan. The facility will initially house approximately 40 Principal Investigators, alongside 250 graduate students, postdoctoral fellows, computer scientists, and support staff. Supported by a generous gift from Hamilton Evans "Tony" James, Executive Vice Chairman of the Manhattan-based investment firm Blackstone, and his wife, Amabel, the 12-story, 65,000-square-foot facility will be housed in a repurposed Mount Sinai building at 3 East 101st Street. "By integrating AI technology across genomics, imaging, pathology, electronic health records, and beyond, Mount Sinai is revolutionizing doctors' capacity to diagnose and treat patients, reshaping the future of health care. Mount Sinai has been at the forefront of AI research and development in health care, and now we stand as one of the first medical schools to establish a dedicated AI research center,” says Eric Nestler, MD, PhD, Director of the Friedman Brain Institute, Dean for Academic and Scientific Affairs and Nash Family Professor in the Nash Family Department of Neuroscience at Icahn School of Medicine at Mount Sinai and Chief Scientific Officer at Mount Sinai Health System . "As AI technology is evolving rapidly, this moment is critical for maintaining leadership in digital health. The Hamilton and Amabel James Center for Artificial Intelligence and Human Health will cultivate an optimal environment for researchers to deepen their understanding, diagnosis, and treatment of human diseases-including the most debilitating-and to advance overall health and well-being.” "If we want to use artificial intelligence for the greater good and make significant progress in health care, investing in AI research and development within academic institutions is essential,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean at Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System . "While large tech companies possess substantial funding and resources to access high-performance equipment, they lack access to a health care system, limiting their progress in the field. This new AI research center at Icahn Mount Sinai will yield transformative discoveries in human health by the integration of research and data, fostering collaboration across multiple programs under one roof.” To construct the new AI center, Mount Sinai modernized an existing building to meet contemporary standards, including updating the facade to align with the aesthetic of other campus buildings. Within the 12 floors of the center, eight will be dedicated to Mount Sinai's AI initiatives. These core facilities include: About Mount Sinai's Windreich Department of AI and Human Health Mount Sinai's Windreich Department of AI and Human Health, the first such department in a U.S. medical school, is committed to advancing and optimizing artificial intelligence and human health. The department is dedicated to harnessing the power of leading-edge tools to revolutionize scientific research and discovery. This commitment is realized through the creation of an "intelligent fabric," seamlessly integrating machine learning and AI-driven decision-making throughout Mount Sinai's entire health system. It includes the distinguished Icahn School of Medicine at Mount Sinai, serving as a central hub for innovative learning. This integration facilitates robust partnerships spanning all research institutes, academic departments, hospitals, and outpatient centers. Through this strategic approach, the Department is accelerating progress in disease prevention, treating severe illnesses, and enhancing the overall quality of life for all. In 2024, the Department's innovative NutriScan AI application, designed to facilitate faster identification and treatment of malnutrition in hospitalized patients, earned Mount Sinai Health System the prestigious Hearst Health Prize. This machine learning tool improves malnutrition diagnosis rates and resource utilization, demonstrating the impactful application of AI in health care. For more information, visit ai.mssm.edu . About the Icahn School of Medicine at Mount Sinai The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population. Ranked 11th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 4,560 full-time scientists, educators, and clinicians work within and across 45 academic departments and 38 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases. Icahn Mount Sinai offers highly competitive MD, PhD, and Master's degree programs, with current enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,685 clinical residents and fellows training throughout the Health System. In addition, more than 560 postdoctoral research fellows are in training within the Health System. A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai's technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public. Icahn Mount Sinai's commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School's programs. Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others. The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai's location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally. ------------------------------------------------------- * Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai. About the Mount Sinai Health System Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time-discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients' medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek's® "The World's Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® "Best Hospitals” and "Best Children's Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® "Best Hospitals” Honor Roll for 2024-2025. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook , Twitter and YouTube . Attachment Ribbon Cutting Photo CONTACT: Mount Sinai Press Office Mount Sinai Press Office [email protected]If you find yourself with a bit of extra cash in your Christmas stocking this year, you might be thinking about some undervalued ASX stocks to add to your portfolio. Here are two of my current favourites. One is a leading Aussie tapping into emerging AI trends by providing data storage solutions. The other is a former market darling down on its luck after releasing an underwhelming outlook for FY25. NextDC has been one of my favourite ASX tech shares to own for years now. However, as more companies incorporate (AI) technology into their everyday operations, the for NextDC only becomes more compelling. NextDC is one of Australia's leading operators of data centres, which are physical facilities that store companies' data and other digital assets. NextDC's data centres are colocation facilities, which means multiple clients can rent space in the data centre at once. This allows companies to outsource their data storage needs so that they don't have to spend a fortune building their own technology infrastructure. I think NextDC is a great share to buy right now because of how rapidly AI, automation, and digitisation are being adopted by large corporations. All this new data needs to be stored somewhere, which could drive a massive surge in demand for data centre space. This is already starting to play out in the . Revenues were up 12% year-on-year to $404.3 million for the financial year ended 30 June 2024, while underlying came in above the company's guidance at $204.3 million. After surging to a 52-week high of $23.51 back in March, Audinate shares have since plunged almost 70% to just $7.31 at the time of writing. However, I think the market has unfairly punished Audinate shares, and they could offer investors an excellent buying opportunity at these prices. Audinate is a aiming to disrupt the audiovisual (AV) technology industry. Its flagship product, called Dante, is designed to replace all the complicated audio and video connections of outdated analogue systems with a digital computer network. It simplifies complex AV systems without compromising sound or image quality, making them far easier to manage. Its customers include hospitality venues, sports and entertainment events, and even churches and other places of worship. There are several good reasons to invest in Audinate. The company is an industry leader with significant intellectual property (IP) behind it, which makes it very difficult for new entrants to take away any of its market share. This gives it a considerable – something investors normally go gaga for. Plus, Audinate's FY24 results (for the year ended 30 June 2024) . Revenues were up 28.4% year-on-year to $91.5 million, and EBITDA was a record $20.4 million. However, investors were concerned about Audinate's near-term outlook. The company identified a number of headwinds that could negatively impact revenues in FY25, including shorter order lead times, higher inventory levels, and a slowdown in demand after the post-COVID recovery. While the company did flag that it expected things to rebound in FY26, many investors decided they didn't want to wait that long and dumped their shares. But this mass sell-off could be a great buying opportunity for those who are still bullish about Audinate's long-term growth potential. Speaking at the time of the results, Audinate CEO Aidan Williams said: Whilst we expect FY25 to be a transitional year, the long-term strategic thesis for Audinate remains unchanged. With the challenges of the last few years behind us, we will redouble our efforts to drive audio & video unit growth, a key building block in our long-term strategy.
A judge on Monday rejected a request to block a San Jose State women’s volleyball team member from playing in a conference tournament on grounds that she is transgender. Monday’s ruling by U.S. Magistrate Judge S. Kato Crews in Denver will allow the player, who has played all season, to continue competing in the Mountain West Conference women’s championship scheduled for later this week in Las Vegas. The ruling comes after a lawsuit was filed by nine current players who are suing the Mountain West Conference to challenge the league’s policies for allowing transgender players to participate. The players argued that letting her compete was a safety risk and unfair. While some media have reported those and other details, neither San Jose State nor the forfeiting teams have confirmed the school has a trans women’s volleyball player. The Associated Press is withholding the player’s name because she has not publicly commented on her gender identity. School officials also have declined an interview request with the player. Judge Crews referred to the athlete as an “alleged transgender” player in his ruling and noted that no defendant disputed that San Jose State rosters a transgender woman volleyball player. He said the players who filed the complaint could have sought relief much earlier, noting that the individual universities had acknowledged that not playing their games against San Jose State this season would result in a forfeit in league standings. He also said injunctions are meant to preserve the status quo. The conference policy regarding forfeiting for refusing to play against a team with a transgender player had been in effect since 2022 and the San Jose State player has been on the roster since 2022 – making that the status quo. The player competed at the college level three previous seasons, including two for San Jose State, drawing little attention. This season’s awareness of her identity led to an uproar among some players, pundits, parents and politicians in a political campaign year. The tournament starts Wednesday and continues Friday and Saturday. San Jose State is seeded second. The judge's order maintains the seedings and pairings for the tournament. Several teams refused to play against San Jose State during the season, earning losses in the official standings. Boise State and Wyoming each had two forfeits while Utah State and Nevada both had one. Southern Utah, a member of the Western Athletic Conference, was first to cancel against San Jose State this year. Nevada’s players stated they “refuse to participate in any match that advances injustice against female athletes,” without providing further details. Crews served as a magistrate judge in Colorado’s U.S. District Court for more than five years before President Joe Biden appointed him to serve as a federal judge in January of this year. ____ Gruver reported from Cheyenne, Wyoming, and Hanson from Helena, Montana. Mead Gruver And Amy Beth Hanson (), The Associated PressStockhead Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. When we were kids eyeing an unobtainable treat or the not-so-imminent arrival of Santa, Mum used to tell us to be patient. Patience, indeed, is a virtue and an admirably quality to exhibit throughout one’s adult life. But there are circumstances when even a Job-like quotient of patience will not suffice – and one of them is waiting for the effect of erectile dysfunction tablets to kick in. According to LTR Pharma, oral drugs such as Viagra and Cialis can take more than an hour to have their desired effects. Yes, there’s such a thing as foreplay but in such a time span the amorous vibe is likely to be surpassed by the imperative of vacuuming the hall or emptying the dishwasher. LTR Pharma is developing a nasally-delivered variant of the same drug class which, on evidence to date, hits peak bloodstream levels within nine to 15 minutes. LTR founder and executive chair Lee Rodne says 50% of men stop taking the current tablets within a year, because of the timing problem and side effects. “A lot of guys don’t realise that Viagra is very variable as a tablet because of the delivery mechanism,” Rodne says. “It has to go through your gut and your liver; sometimes it is effective but sometimes it is not effective at all.” The rise and rise of LTR Rodne founded LTR based on technology acquired from California’s Strategic Drug Solutions, with pharmacologist Prof Moses Chow credited as the inventor. Then an executive with iron-ore producer Fortescue Metals, Rodne was hand-picked by Fortescue founder Dr Andrew ‘Twiggy’ Forrest to lead the company’s health spin-off Allied Medical. Rodne led Allied for 10 years, merging it with Biomd to become Allied Healthcare and then Admedus and now heart transcatheter play Anteris Technologies. Rodne’s Allied experience led him to a group of medical researchers and manufacturers who asked him for help with a project to make erectile dysfunction treatments more effective and consistent. Under the deal with Strategic Drug Solutions, LTR Pharma can use the technology in any way, but its current sole focus is on erectile dysfunction (ED). LTR Pharma listed on December 11 last year, having raised $7 million at 20 cents apiece. Rodne owns 34% of the company, with fellow director Dr Julian Chick accounting for 19.7%. Chick has been involved in no fewer than 16 start-ups and helmed the ASX-listed Avexa, which tried to develop an HIV drug but eventually went coal mining in Alabama instead. He is the chair of pot play Cann Group and is behind the impending ASX listing of a nerve-regeneration company called Renerve. About Spontan Spontan – as in spontaneous – is a drug and device combination to deliver vardenafil, the basis of Levitra and Staxyn. Vardenafil is a PDE5 inhibitor, which target receptors that relax muscles and increase blood flow to the penis. Other PDE5 inhibitors are behind Pfizer’s Viagra (sildenafil), the first to market in 1998, Cialis (tadalafil) and Stendra (avanafil). All these PDE5s are pretty much same-same, but vardenafil was deemed the most suitable for nasal reformulations. Rodne says current side-effects include heartburn and joint pain, which are all the result of the oral tablets going through the gastro-intestinal tract. Spontan, of course, goes straight to the blood stream. Why not earlier? Rodne says Spontan currently faces no competition, but the lingering question is why big pharma - notably trailblazer Pfizer with its ‘Pfizer riser’ - didn’t crack the nasal channel. Cialis, Viagra and Levitra, the three biggest-selling erectile dysfunction drugs are now off-patent and subject to generic competition. Stendra’s patent expires in April 2025. “Pfizer looked into it but it’s very hard to work because of the chemical structure,” he says. “It tends crystallise when in liquid form, so you can’t just crush up a chemical tablet, put it in a bottle and expect to be able to spray it.” The nub of LTR’s smarts is the ability to keep the drug soluble and enhance drug interaction. Where’s the evidence? LTR Pharma’s proof of efficacy to date is a small local trial and ‘real world’ usage evidence. On June 7 this year the company said an 18-man bio-availability trial showed Spontan hit peak bloodstream levels in nine to 15 minutes – an average of 12 minutes – compared with an average 56 minutes and as much as 150 minutes for oral vardenafil. The healthy adults were given two single 5.0mg doses of Spontan, as well as a 10mg dose of the oral version after a respectable crossover period. Given the drug is known to be effective once it reaches the bloodstream, that’s all the trial had to prove. In other words, the subjects weren’t being assessed on the quality of erections and lovemaking by a white-coated researcher at the end of the bed. Early in the piece, LTR became eligible for the local Therapeutics Goods Administration’s special access scheme and then the authorised prescriber scheme. These allow unapproved treatments to be administered. Initially, Spontan was prescribed by two men’s health doctors, but has spread to a broader cohort. A notable prescriber is urology expert Prof Eric Chung of the University of Queensland. Taking it slowly Rodne says the company won’t reveal current patient use – which is on the rise – because it doesn’t want investors to focus on sales for what is still a research and development-stage company transitioning to commercial phase. “Before we do that fully, we want specific feedback on patient use, such as whether they are using it in combination with other products,” he says. “We also want to produce education videos on how to use the product and we have some more packaging work to do and ensure patients can follow the instructions clearly.” That said, the company hopes the trial and the real-world data will support a marketing application to the TGA initially and the US Food and Drug Administration in early to mid-2025. The FDA filing is expected to be under the 505(b)(2) route, pertaining to a “change in route of administration for already approved drug”. “We expect to use the data packages for both agencies, but our home market is important for us,” Rodne says. While the requirement for further trials is unclear, the company expects more investigator-led studies here, with a standard requirement for an animal toxicology study. Take your partners In the meantime, LTR is in confidential licensing and partnering discussions with pharmaceutical companies. “We will run these discussions until 2025 and see what sort of value we can create,” Rodne says. “They would not waste their time if they were not interested.” In mid-August, LTR entered a co-development agreement with the New York-listed Aptar Pharma, a developer of nasal spray medicines used by drug companies including Pfizer and Johnson & Johnson. “They don’t partner with everyone: it needs to be a differentiated product with a big market and significant data.” As LTR’s device partner, Aptar will carry out market and regulatory readiness work, such as meeting with the agencies and formulation studies. “Aptar has more than 25 products approved with the FDA, so we don’t have to prove in the same way we don’t have to prove the drug works, because it has already been approved in oral form.” Indeed, the PDE5 tablets have been tested on hundreds of thousands – if not millions - of patients and cost more than US$1 billion to develop. Telehealth Earlier this month, LTR entered a joint venture with a West Australian men's health group, the Restorative Sexual Health Clinic, for an online healthcare platform. “The online platform will provide a discrete and convenient channel for men to access professional healthcare services and prescribed treatments,” Rodne says. The platform is expected to launch in the March quarter of next year. Finances and performance Shortly after the positive trial results, LTR bolstered its $7 million of IPO funds with a $10.5 million placement, struck at 73 cents apiece (a 19% discount). Rodne says LTR has sufficient cash – three years – beyond the likely timelines for regulatory approval and commercial partnering. The company intends to devote some of the funds to building an online sales channel, to avail of the rapid rise in digital prescriptions (in fact, the lion’s share of erectile dysfunction scripts is written remotely). LTR Pharma’s annual report shows a contingent liability of US$3 million, by way of potential milestone payments to Strategic Drug Solutions. LTR Pharma shares have always traded above their 20 cents listing price, bottoming at 27 cents two days after the IPO and peaking at $2.06 on October 10 this year. Dr Boreham’s diagnosis Rodne says that as a company focused on a single re-purposed drug, LTR Pharma is a simple story to understand. Spontan also addresses a high unmet need, with an estimated 322 million of the world’s blokes estimated to suffer erectile difficulties. Of these, close to half are in China, which might explain the nation’s sagging birth rate. Australian blokes can’t exactly stand proud, either, with the condition affecting more than 60% of over 45s. The value of the erectile dysfunction market is estimated at US$4.52 billion, with the US accounting for 30% despite having less than 10% of the sufferers. The market is expected to grow to US$6 billion by 2028, despite what Rodne describes as a complete lack of erectile dysfunction treatment innovation. While LTR Pharma is an easy-to-understand proposition, there’s no plan B if Spontan fails to gain market approval or flops at launch. An unexpected rival could also emerge, but Rodne believes the coast is clear. The endgame for LTR is unclear – it might go all the way to market on its own – but it would be stiff for the company to fail at this point. After all, Spontan would seem to be a great way for, say, Pfizer, to re-establish patent life on its famed blue pill. At a glance ASX code: LTP Share price: $1.205 Shares on issue: 153,901,979 Market cap: $102.17 million Executive chair: Lee Rodne Board: Rodne, Dr Julian Chick, Maja McGuire Financials (year to June 30, 2024): revenue nil, loss of $9.95 million ($1.45 million deficit previously), cash of $3.1 million (up 79%) ahead of $10.5 million capital raising Identifiable major shareholders: Rodne 34% interest, Strategic Drug Solutions 3.8%, Trexapharm 2.7%. Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. He doesn’t have a Job-like quotient of patience, so will ensure the dishwasher stays off at the crucial moment. This column first appeared in Biotech Daily. At Stockhead we tell it like it is. While LTR Pharma is a Stockhead advertiser at the time of writing, it did not sponsor this article. Originally published as Dr Boreham’s Crucible: The rise and rise of LTR Pharma More related stories Stockhead Trump’s tariffs hits ASX, but EML jumps 24pc The ASX has dropped on Tuesday following Trump’s tariff announcement, but EML Payments surged after reporting strong Q1 results. Read more Stockhead Two biotech IPOs test strength of market Two new biotech companies – Vitrafy and Renerve – listed today, breaking an eight-month drought of life sciences IPOs on the ASX. Read more